prochlorperazine maleate tablet, film coated
pd-rx pharmaceuticals, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine maleate tablets are indicated for the control of severe nausea and vomiting. prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine maleate tablets should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of out
prochlorperazine maleate tablet
northwind pharmaceuticals - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 5 mg in 6
pms-prochlorperazine tab 10mg tablet
pharmascience inc - prochlorperazine (prochlorperazine maleate) - tablet - 10mg - prochlorperazine (prochlorperazine maleate) 10mg - phenothiazines
pms-prochlorperazine tab 5mg tablet
pharmascience inc - prochlorperazine (prochlorperazine maleate) - tablet - 5mg - prochlorperazine (prochlorperazine maleate) 5mg - phenothiazines
pms-prochlorperazine suppositoires 10mg suppository
pharmascience inc - prochlorperazine - suppository - 10mg - prochlorperazine 10mg - phenothiazines
prochlorazine tablet
aa pharma inc - prochlorperazine (prochlorperazine maleate) - tablet - 10mg - prochlorperazine (prochlorperazine maleate) 10mg - phenothiazines
prochlorazine tablet
aa pharma inc - prochlorperazine (prochlorperazine maleate) - tablet - 5mg - prochlorperazine (prochlorperazine maleate) 5mg - phenothiazines
prochlorperazine- prochlorperazine suppository
nucare pharmaceuticals,inc. - prochlorperazine (unii: yhp6ylt61t) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine suppositories, usp 25 mg are indicated in the control of severe nausea and vomiting in adults. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). do not use in pediatric surgery. do not use in children under 2 years of age or under 20 lbs. do not use in children for conditions for which dosage has not been established.
prochlorperazine tablet
pharmpak, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that pr
prochlorperazine tablet
pharmpak, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that pr